Documents
Application Sponsors
NDA 204119 | HETERO DRUGS LTD | |
Marketing Status
None (Tentative Approval) | 001 |
Application Products
001 | TABLET; ORAL | 600MG;300MG;300MG | 0 | EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE | EFAVIRENZ;LAMIVUDINE;TENOFOVIR DISOPROXIL FUMARATE |
FDA Submissions
TYPE 4; Type 4 - New Combination | ORIG | 1 | TA | 2017-06-30 | PRIORITY |
Submissions Property Types
CDER Filings
HETERO DRUGS LTD
cder:Array
(
[0] => Array
(
[ApplNo] => 204119
[companyName] => HETERO DRUGS LTD
[docInserts] => ["",""]
[products] => [{"drugName":"EFAVIRENZ, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE","activeIngredients":"EFAVIRENZ;LAMIVUDINE;TENOFOVIR DISOPROXIL FUMARATE","strength":"600MG;300MG;300MG","dosageForm":"TABLET; ORAL","marketingStatus":"None (Tentative Approval)","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"06\/30\/2017","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"Type 4 - New Combination","reviewPriority":"PRIORITY","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2012\\\/204119Orig1s000TAltr.pdf\"}]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2017-06-30
)
)